Cancer BiologybioRxiv
Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer
P. Mao, O. Cohen, K. J. Kowalski…·N. Wagle
This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.
DOI 10.1158/1078-0432.ccr-19-3958